Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis
- PMID: 18616782
- PMCID: PMC2829655
- DOI: 10.1111/j.1365-2133.2008.08711.x
Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis
Abstract
Background: Reliable and validated measures of skin disease severity are needed for cutaneous dermatomyositis (DM). Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Dermatomyositis Skin Severity Index (DSSI) and Cutaneous Assessment Tool (CAT) skin indices have been developed as outcome instruments.
Objectives: We sought to demonstrate reliability and validity of the CDASI, and to compare the CDASI with other potential tools for use in measuring disease severity in cutaneous dermatomyositis.
Patients and methods: CDASI has four activity and two damage measures, with scores from 0 to 148. DSSI assesses activity based on body surface area and severity on a scale of 0-72. CAT uses 21 activity and damage items, for a range of 0-175 for activity and 0-33 for damage. Ten dermatologists used the instruments to score the same 12-16 patients in one session. Global validation measures were administered to physicians and patients.
Results: Global validation measures correlated with the three outcome instruments (P < 0.0001). CAT displayed lower inter- and intrarater reliability relative to the CDASI. All scales correlate better with physician than patient global skin measures.
Conclusions: It appears that the CDASI may be a useful outcome measure for studies of cutaneous DM. Further testing to compare responsiveness of all three measures is necessary.
Conflict of interest statement
Similar articles
-
Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool-Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists.Br J Dermatol. 2017 Oct;177(4):1086-1092. doi: 10.1111/bjd.15596. Epub 2017 Jul 31. Br J Dermatol. 2017. PMID: 28421601 Free PMC article.
-
Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM.J Invest Dermatol. 2012 Apr;132(4):1117-24. doi: 10.1038/jid.2011.440. Epub 2012 Jan 5. J Invest Dermatol. 2012. PMID: 22217740 Free PMC article.
-
The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) among dermatologists, rheumatologists and neurologists.Br J Dermatol. 2017 Feb;176(2):423-430. doi: 10.1111/bjd.15140. Epub 2016 Dec 22. Br J Dermatol. 2017. PMID: 28004387 Free PMC article.
-
The validity and utility of the Cutaneous Disease Area and Severity Index (CDASI) as a clinical outcome instrument in dermatomyositis: A comprehensive review.Semin Arthritis Rheum. 2020 Jun;50(3):458-462. doi: 10.1016/j.semarthrit.2020.01.002. Epub 2020 Jan 11. Semin Arthritis Rheum. 2020. PMID: 32057402 Free PMC article. Review.
-
Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI).Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11(0 11):S118-57. doi: 10.1002/acr.20532. Arthritis Care Res (Hoboken). 2011. PMID: 22588740 Free PMC article. Review. No abstract available.
Cited by
-
Pruritogenic molecules in the skin of patients with dermatomyositis.Front Med (Lausanne). 2023 May 11;10:1168359. doi: 10.3389/fmed.2023.1168359. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37250649 Free PMC article.
-
Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial.J Invest Dermatol. 2022 Oct;142(10):2651-2659.e1. doi: 10.1016/j.jid.2022.03.029. Epub 2022 Apr 29. J Invest Dermatol. 2022. PMID: 35490744 Free PMC article. Clinical Trial.
-
Clinical Characteristics and Management of Patients With Clinical Amyopathic Dermatomyositis: A Retrospective Study of 64 Patients at a Tertiary Dermatology Department.Front Med (Lausanne). 2021 Dec 2;8:783416. doi: 10.3389/fmed.2021.783416. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34926528 Free PMC article.
-
Updates on Juvenile Dermatomyositis from the Last Decade: Classification to Outcomes.Rheum Dis Clin North Am. 2021 Nov;47(4):669-690. doi: 10.1016/j.rdc.2021.07.003. Epub 2021 Sep 2. Rheum Dis Clin North Am. 2021. PMID: 34635298 Free PMC article. Review.
-
Update on Epidemiology and Clinical Assessment Tools of Cutaneous Lupus Erythematosus and Dermatomyositis.Curr Dermatol Rep. 2013 Mar;2(1):48-57. doi: 10.1007/s13671-012-0037-3. Epub 2013 Jan 24. Curr Dermatol Rep. 2013. PMID: 33585073 Free PMC article.
References
-
- Hundley JL, Carroll CL, Lang W, et al. Cutaneous symptoms of dermatomyositis significantly impact patients’ quality of life. J Am Acad Dermatol. 2006;54:217–20. - PubMed
-
- Sontheimer RD. Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin. 2002;20:387–408. - PubMed
-
- Sontheimer RD. Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis. Curr Opin Rheumatol. 1999;11:475–82. - PubMed
-
- Williams HC. Is a simple generic index of dermatologic disease severity an attainable goal? Arch Dermatol. 1997;133:1451–1452. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
